AGREEMENT AND AMENDMENT NO. 2
Exhibit 10.22
This AGREEMENT AND AMENDMENT NO. 2 is made this 1st day of April 2015, and effective as of January 1, 2015, by and between ORAMED PHARMACEUTICALS INC., a Delaware corporation with a mailing address at Hi-Tech Park 2/4 Xxxxx Xxx, Xxxxxxxxx 00000 Xxxxxx (the “Company”), and Xxxxxxx Xxxxxxxxxx, M.D., with an address 000 Xxxx 00xx Xxxxxx Xxx Xxxx, XX 00000 (“Berelowitz”).
WHEREAS:
| A. | The Company and Berelowitz are parties to the Agreement dated as of November 26, 2013, as amended on July 16, 2014 (together, the “Original Agreement”); and |
| B. | The Company and Berelowitz wish to amend the Original Agreement to extend the term thereof for an additional twelve months. |
NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows:
| 1. | Amendment to Section 1.2. Section 1.2 of the Original Agreement is hereby amended and restated in its entirety to read as follows: |
| “2.1 | Term. Unless terminated earlier in accordance with the provisions hereof, the term of engagement under this Agreement shall commence on January 1, 2015 (the “Effective Date”) and shall continue for a period of twelve months (the “Term”).” |
| 2. | Ratification. As amended hereby, the Original Agreement is ratified and confirmed and all other terms and conditions remain in full force and effect. |
[Signature page follows.]
| -2- |
IN WITNESS WHEREOF the parties hereto have executed this Agreement and Amendment No. 2 effective as of the date and year first above written.
| ORAMED PHARMACEUTICALS INC. | |||
| Per: | /s/ Xxxxx Xxxxxx, /s/ Xxxxx Xxxxxx |
/s/ Xxxxxxx Xxxxxxxxxx | |
XXXXXXX XXXXXXXXXX M.D. | |||
| Name: | Xxxxx Xxxxxx / Xxxxx Xxxxxx | ||
| Title: | Chief Executive Officer / CFO | ||
